CF
BTAI icon

CNA Financial’s BioXcel Therapeutics BTAI Stock Holding History

CNA Financial’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-897
Closed -$292K – 189
2021
Q4 		$292K Buy
897
+267
+42% +$115K 0.08% 183
2021
Q3 		$306K Buy
630
+38
+6% +$16.7K 0.08% 186
2021
Q2 		$275K Buy
592
+48
+9% +$26.2K 0.08% 188
2021
Q1 		$376K Buy
544
+72
+15% +$57.9K 0.12% 175
2020
Q4 		$349K Buy
472
+64
+16% +$49.9K 0.11% 178
2020
Q3 		$283K Buy
408
+57
+16% +$42.8K 0.1% 172
2020
Q2 		$298K Buy
+351
New +$229K 0.12% 164

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CNA Financial's BTAI Position: Q1 2022 in Review

CNA Financial sold out of BioXcel Therapeutics (BTAI) in Q1 2022, closing a stake of 897 shares — an estimated $292K sold.

CNA Financial first reported a position in BTAI in Q2 2020 and held it in 7 quarters. The position peaked at $376K in Q1 2021. 96 funds tracked by Wall St. Rank hold BTAI as of Q1 2022.

  • CNA Financial reported no remaining BioXcel Therapeutics position as of Q1 2022 after selling out during the quarter.
  • CNA Financial sold 897 BioXcel Therapeutics shares in Q1 2022, an estimated $292K.
  • CNA Financial first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 7 quarters.
  • CNA Financial's BioXcel Therapeutics position peaked at $376K in Q1 2021.
  • 96 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2022.

Based on CNA Financial's 13F filing for Q1 2022, filed 10 May 2022.